EU PH



DATE
November 27-28, 2026

VENUE
Hotel Courtyard Marriott,
1020 Vienna

18th EU PH MEETING 2026 | PROGRAM

MEDIZINISCHE UNIVERSITÄT WIEN

Supported by AOP HEALTH

The EU PH Meeting has been granted 11 DFP accreditation points from the Austrian Medical Chamber.

Friday, 27 November 2026

From 13:30	**Registration & Light Lunch**	
15:00	Welcome & Opening	Irene Lang, Bianca Tan
15:15-18:00	**Interactive clinical case forum: Real-world challenges & decisions**	
15:15-16:30	**Case presentations I** *Chairs: Nika Skoro-Sajer, Roberto Badagliacca*	
	Between evidence and reality: What to do when the patient doesn't fit the guidelines? *(Austria)*	Thomas Vockenhuber
	Right at heart, wrong at start *(Germany)*	Elena Pfeuffer-Jovic
	Treat the risk score or rescue the right ventricle? Redefining the role of parenteral treprostinil in PAH *(Romania)*	Ioan Tilea
	From hemodynamic insufficiency to clinical improvement: The impact of treprostinil dose escalation in idiopathic PAH *(Poland)*	Kamil Jonas
16:30-17:45	**Case presentations II** *Chairs: Regina Steringer-Mascherbauer, Pavel Jansa*	
	A rare genetic case of PAH *(Austria)*	Matteo Burda / AKH
	PAH risk stratification in timing for treatment escalation and LTx evaluation: The importance of timely referral *(Sweden)*	Abdulla Ahmed
	Timely escalation to parenteral prostacyclin in PAH *(Italy)*	Daniele Prati
	Pulmonary hypertension: When the map and compass disagree *(Saudi Arabia)*	Shaya Ahmed Alshaya
19:00	**Departure for Dinner**	

Saturday, 28 November 2026

09:00-09:10	**Welcome & Introduction**	Irene Lang
09:10-10:45	**Session I:** How we understand pulmonary hypertension *Chairs: Irene Lang, Christian Gerges*	
09:10-09:30	State of the art: Pathophysiology of pulmonary arterial hypertension	Laurent Savale
09:30-09:50	From vasodilation to disease modification: The next frontier?	Khodr Tello
09:50-10:10	Treprostinil as a hematologic modulator	Tiziano Barbui
10:10-10:45	**Coffee break**	
10:45-11:45	**Session II:** Clinical insights for precision treatment in PAH *Chairs: Göran Radegran, Grzegorz Kopeć*	
10:45-11:00	Haemodynamic lung biopsy – the basis for treatment decision	Christian Gerges
11:00-11:15	Impact of phenotyping to guide treatment decisions	Michele D'Alto
11:15-11:30	New role of RV-PA coupling	Khodr Tello
11:30-11:45	Panel discussion	Faculty
11:45-12:00	**Short Update:** Treatment of PAH – ERS clinical practice guidelines	Gabor Kovacs
12:00-13:00	**Lunch break**	
13:00-14:30	**Session III:** Looking beyond risk stratification: Time for more ambition *Chairs: Gabor Kovacs, Michele D´Alto*	
13:00-13:15	Beyond green: Redefining treatment success in PAH	Hans Klose
13:15-13:30	Treat-to-target in PAH: Treatment optimization in the 4-pathway era	Roberto Badagliacca
13:30-13:45	Timing matters: Impact of early parenteral prostacyclin initiation on risk status and remission in PAH	Athénais Boucly
13:45-14:00	TripleTRE – key updates	Rui Placido
14:00-14:15	Panel discussion	Faculty
14:15-14:30	**Break**	

Hotel Courtyard Marriott
1020 Vienna

HYBRID MEETING:
Please scan the QR-Code to join the meeting virtually!

Saturday, 28 November 2026

14:30-15:15	**Session IV:** Pediatric PH and TrePaed *Chairs: Sulaima Albinni, Joseph Pattathu*	
14:30-14:45	Pediatric PH is not small adult PH: Evidence gaps and AEPC signals	Joseph Pattathu
14:45-15:00	TrePaed: Pediatric treprostinil evidence and study rationale	tbd
15:00-15:15	Panel discussion	Faculty
15:15-16:00	**Session V:** Building evidence and supporting treatment decisions *Moderator: Sulaima Albinni*	
15:15-15:30	Navigating treatment decisions with patients and families & real-life data	Silvia Papa, Ralf Lenhard
15:30-15:50	Interactive discussion	
15:50-16:00	**Summary and Closing Remarks**	



MEDIZINISCHE UNIVERSITÄT WIEN

EU PH

AOP HEALTH